LIPOSYN 20%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LIPOSYN 20% (LIPOSYN 20%).
Liposyn 20% is an intravenous fat emulsion providing essential fatty acids (linoleic and linolenic acids) and triglycerides. It serves as a caloric source and prevents essential fatty acid deficiency by supplying substrate for energy metabolism and cell membrane synthesis.
| Metabolism | Metabolized by lipolysis via lipoprotein lipase in peripheral tissues, followed by beta-oxidation of free fatty acids in the liver and other tissues. |
| Excretion | Lipids are metabolized; <10% excreted renally as free fatty acids; biliary/fecal excretion minimal. |
| Half-life | Triglyceride clearance half-life approximately 30-60 minutes; depends on lipase activity and clinical status. |
| Protein binding | Lipoproteins and albumin; minimal binding of intact triglycerides; free fatty acids >99% bound to albumin. |
| Volume of Distribution | 0.1-0.2 L/kg; reflects initial distribution in plasma and interstitial space. |
| Bioavailability | Intravenous: 100% (only route). |
| Onset of Action | Intravenous: immediate delivery to circulation; clinical effect (caloric supply) occurs within minutes. |
| Duration of Action | Provides sustained energy over 24 hours with continuous infusion; intermittent infusion effects last until next dose. |
Intravenous infusion: 1-2 g/kg/day (as soybean oil) initially, up to 2.5 g/kg/day, not to exceed 50% of total caloric intake; infusion rate not to exceed 0.1 g/kg/hour for first 30 minutes; if no adverse reactions, may increase to 0.2 g/kg/hour.
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based dose modifications for lipid emulsions; monitor serum triglycerides and electrolytes; use with caution in acute kidney injury due to risk of hypertriglyceridemia. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B/C: contraindicated or use with extreme caution; reduce dose by 50% and monitor liver function and triglycerides closely. |
| Pediatric use | Intravenous infusion: 0.5-1 g/kg/day initially, increase by 0.5-1 g/kg/day to maximum 3 g/kg/day for term infants and 4 g/kg/day for preterm infants; infusion rate not to exceed 0.17 g/kg/hour. |
| Geriatric use | No specific dose adjustment; initiate at lower end of dosing range (e.g., 1 g/kg/day) and titrate slowly due to potential decreased clearance and increased risk of hypertriglyceridemia; monitor triglycerides and fluid status. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LIPOSYN 20% (LIPOSYN 20%).
| Breastfeeding | Excretion in human milk unknown. Intravenous fat emulsion is unlikely to achieve high concentrations in milk. M/P ratio not available. Use with caution in nursing mothers; benefits vs risks should be considered. |
| Teratogenic Risk | Liposyn 20% (intravenous fat emulsion) is not teratogenic; no fetal risks identified in animal studies. No adequate human studies in first trimester; use only if clearly needed. In second and third trimesters, no increased risk of malformations reported. Potential risks from maternal metabolic disturbances if administered improperly. |
■ FDA Black Box Warning
Deaths in preterm infants have been reported with intravenous fat emulsions; autopsy findings included intravascular fat accumulation. Preterm and low-birth-weight infants have poor clearance of intravenous fat emulsion and are at increased risk of fat overload syndrome.
| Serious Effects |
["Hypersensitivity to egg, soybean, or peanut proteins","Severe hyperlipidemia","Lipoid nephrosis","Acute pancreatitis with hyperlipidemia"]
| Precautions | Monitor for signs of fat overload syndrome (hepatomegaly, jaundice, coagulopathy, hyperlipidemia, thrombocytopenia, fever). Use with caution in patients with hyperlipidemia, pancreatitis, severe hepatic impairment, pulmonary disease, or sepsis. Avoid rapid infusion. Do not use if emulsion shows oil separation or discoloration. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal triglycerides, liver function tests, and coagulation parameters; observe for signs of fat overload syndrome (hepatomegaly, splenomegaly, thrombocytopenia). Fetal monitoring via ultrasound for growth and well-being if maternal condition warrants. |
| Fertility Effects | No known adverse effects on fertility. Intravenous fat emulsion is used as a nutritional supplement; no direct reproductive toxicity reported in animal studies. |